<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 14 Sep 2023 20:08:28 +0000</lastbuilddate>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Age-induced senescence impairs the neurovascular interface in the heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 13. doi: 10.1038/s41569-023-00936-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704795</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00936-5>10.1038/s41569-023-00936-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704795</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Harman</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Age-induced senescence impairs the neurovascular interface in the heart</dc:title>
<dc:identifier>pmid:37704795</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00936-5</dc:identifier>
</item>
<item>
<title>Complete revascularization in MI: role in older patients and optimal timing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704794/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 13. doi: 10.1038/s41569-023-00933-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704794/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704794</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00933-8>10.1038/s41569-023-00933-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704794</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Complete revascularization in MI: role in older patients and optimal timing</dc:title>
<dc:identifier>pmid:37704794</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00933-8</dc:identifier>
</item>
<item>
<title>Reply: Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704318/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):e103. doi: 10.1016/j.jacc.2023.06.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704318/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704318</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.042>10.1016/j.jacc.2023.06.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704318</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</dc:title>
<dc:identifier>pmid:37704318</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.042</dc:identifier>
</item>
<item>
<title>Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704317/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):e101. doi: 10.1016/j.jacc.2023.05.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704317/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704317</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.071>10.1016/j.jacc.2023.05.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704317</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Fabio Barili</dc:creator>
<dc:creator>Amedeo Anselmi</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:creator>Miguel Sousa Uva</dc:creator>
<dc:creator>Alessandro Parolari</dc:creator>
<dc:creator>International Evidence Grading Research Initiative Targeting Transparency and Quality (INTEGRITTY)</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</dc:title>
<dc:identifier>pmid:37704317</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.071</dc:identifier>
</item>
<item>
<title>Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704316/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>Centers specializing in coronary function testing are critical to ensure a systematic approach to the diagnosis and treatment of angina with nonobstructive coronary arteries (ANOCA). Management leveraging lifestyle, pharmacology, and device-based therapeutic options for ANOCA can improve angina burden and quality of life in affected patients. Multidisciplinary care teams that can tailor and titrate therapies based on individual patient needs are critical to the success of comprehensive programs....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1264-1279. doi: 10.1016/j.jacc.2023.06.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Centers specializing in coronary function testing are critical to ensure a systematic approach to the diagnosis and treatment of angina with nonobstructive coronary arteries (ANOCA). Management leveraging lifestyle, pharmacology, and device-based therapeutic options for ANOCA can improve angina burden and quality of life in affected patients. Multidisciplinary care teams that can tailor and titrate therapies based on individual patient needs are critical to the success of comprehensive programs. As coronary function testing for ANOCA is more widely adopted, collaborative research initiatives will be fundamental to improve ANOCA care. These efforts will require standardized symptom assessments and data collection, which will propel future large-scale clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704316/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704316</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.044>10.1016/j.jacc.2023.06.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704316</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Nathaniel R Smilowitz</dc:creator>
<dc:creator>Megha Prasad</dc:creator>
<dc:creator>R Jay Widmer</dc:creator>
<dc:creator>Olga Toleva</dc:creator>
<dc:creator>Odayme Quesada</dc:creator>
<dc:creator>Nadia R Sutton</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Manoj Kesarwani</dc:creator>
<dc:creator>Michael P Savage</dc:creator>
<dc:creator>Joseph M Sweeny</dc:creator>
<dc:creator>Katherine B Janaszek</dc:creator>
<dc:creator>Ailin Barseghian El-Farra</dc:creator>
<dc:creator>Noa Holoshitz</dc:creator>
<dc:creator>Ki Park</dc:creator>
<dc:creator>Ahmed Albadri</dc:creator>
<dc:creator>John A Blair</dc:creator>
<dc:creator>Allen Jeremias</dc:creator>
<dc:creator>Kathleen E Kearney</dc:creator>
<dc:creator>Yuhei Kobayashi</dc:creator>
<dc:creator>Steven E S Miner</dc:creator>
<dc:creator>Bruce A Samuels</dc:creator>
<dc:creator>Samit M Shah</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Janet Wei</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Jeffery W Moses</dc:creator>
<dc:creator>Timothy D Henry</dc:creator>
<dc:creator>Jennifer A Tremmel</dc:creator>
<dc:creator>Microvascular Network (MVN)</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37704316</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.044</dc:identifier>
</item>
<item>
<title>Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704315/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>Angina with nonobstructive coronary arteries (ANOCA) is increasingly recognized and may affect nearly one-half of patients undergoing invasive coronary angiography for suspected ischemic heart disease. This working diagnosis encompasses coronary microvascular dysfunction, microvascular and epicardial spasm, myocardial bridging, and other occult coronary abnormalities. Patients with ANOCA often face a high burden of symptoms and may experience repeated presentations to multiple medical providers...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1245-1263. doi: 10.1016/j.jacc.2023.06.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Angina with nonobstructive coronary arteries (ANOCA) is increasingly recognized and may affect nearly one-half of patients undergoing invasive coronary angiography for suspected ischemic heart disease. This working diagnosis encompasses coronary microvascular dysfunction, microvascular and epicardial spasm, myocardial bridging, and other occult coronary abnormalities. Patients with ANOCA often face a high burden of symptoms and may experience repeated presentations to multiple medical providers before receiving a diagnosis. Given the challenges of establishing a diagnosis, patients with ANOCA frequently experience invalidation and recidivism, possibly leading to anxiety and depression. Advances in scientific knowledge and diagnostic testing now allow for routine evaluation of ANOCA noninvasively and in the cardiac catheterization laboratory with coronary function testing (CFT). CFT includes diagnostic coronary angiography, assessment of coronary flow reserve and microcirculatory resistance, provocative testing for endothelial dysfunction and coronary vasospasm, and intravascular imaging for identification of myocardial bridging, with hemodynamic assessment as needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704315/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704315</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.043>10.1016/j.jacc.2023.06.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704315</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Bruce A Samuels</dc:creator>
<dc:creator>Samit M Shah</dc:creator>
<dc:creator>R Jay Widmer</dc:creator>
<dc:creator>Yuhei Kobayashi</dc:creator>
<dc:creator>Steven E S Miner</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Allen Jeremias</dc:creator>
<dc:creator>Ahmed Albadri</dc:creator>
<dc:creator>John A Blair</dc:creator>
<dc:creator>Kathleen E Kearney</dc:creator>
<dc:creator>Janet Wei</dc:creator>
<dc:creator>Ki Park</dc:creator>
<dc:creator>Ailin Barseghian El-Farra</dc:creator>
<dc:creator>Noa Holoshitz</dc:creator>
<dc:creator>Katherine B Janaszek</dc:creator>
<dc:creator>Manoj Kesarwani</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Megha Prasad</dc:creator>
<dc:creator>Odayme Quesada</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Michael P Savage</dc:creator>
<dc:creator>Nathaniel R Smilowitz</dc:creator>
<dc:creator>Nadia R Sutton</dc:creator>
<dc:creator>Joseph M Sweeny</dc:creator>
<dc:creator>Olga Toleva</dc:creator>
<dc:creator>Timothy D Henry</dc:creator>
<dc:creator>Jeffery W Moses</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Jennifer A Tremmel</dc:creator>
<dc:creator>Microvascular Network (MVN)</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37704315</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.043</dc:identifier>
</item>
<item>
<title>Transplant in Single Ventricle Physiology: The Fourth Stage?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704314/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1242-1244. doi: 10.1016/j.jacc.2023.06.038.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704314/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704314</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.038>10.1016/j.jacc.2023.06.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704314</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Daphne T Hsu</dc:creator>
<dc:creator>George K Lui</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transplant in Single Ventricle Physiology: The Fourth Stage?</dc:title>
<dc:identifier>pmid:37704314</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.038</dc:identifier>
</item>
<item>
<title>Survival After Cardiac Transplantation in Adults With Single-Ventricle Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704313/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among adult CHD transplant recipients, single-ventricle physiology correlated with higher short-term mortality. However, 10-year conditional survival was similar for biventricular and most single-ventricle CHD patients, and notably better for biventricular CHD patients compared to non-CHD heart transplant recipients. These findings have significant implications towards patient selection and listing strategies, easing concerns related to heart transplantation in adults with CHD and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1226-1241. doi: 10.1016/j.jacc.2023.06.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Without large-scale analyses of adults with single-ventricle congenital heart disease (CHD) undergoing heart transplantation, little evidence exists to guide listing practices and patient counseling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to evaluate survival after heart transplantation in adults with single and biventricular CHD and compare it to that of non-CHD transplant recipients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this 15-year (2005-2020) retrospective analysis, outcome-blinded investigators used probability-linkage to merge the National (Nationwide) Inpatient Sample and Organ Procurement and Transplantation Network data sets.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 382 adult (≥18 years of age) heart transplant recipients with CHD, 185 (48%) had single-ventricle physiology. Compared to biventricular CHD, single-ventricle patients showed significantly reduced survival at 1 (80% vs 91%; HR: 2.50; 95% CI: 1.40-4.49; P = 0.002) and 10 years (54% vs 71%; HR: 2.10; 95% CI: 1.38-3.18; P &lt; 0.001). Among patients who survived the first post-transplantation year, biventricular CHD patients exhibited similar 10-year survival as single-ventricle patients, except for those with hypoplastic left heart syndrome (79% vs 71%; HR: 1.58; 95% CI: 0.85-2.92; P = 0.15). Additionally, biventricular CHD transplant recipients showed significantly better 10-year conditional survival compared to their non-CHD counterparts (79% vs 68%; HR: 0.73; 95% CI: 0.59-0.90; P = 0.003).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among adult CHD transplant recipients, single-ventricle physiology correlated with higher short-term mortality. However, 10-year conditional survival was similar for biventricular and most single-ventricle CHD patients, and notably better for biventricular CHD patients compared to non-CHD heart transplant recipients. These findings have significant implications towards patient selection and listing strategies, easing concerns related to heart transplantation in adults with CHD and destigmatizing most subtypes of single-ventricle CHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704313/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704313</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.037>10.1016/j.jacc.2023.06.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704313</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Syed Shahyan Bakhtiyar</dc:creator>
<dc:creator>Sara Sakowitz</dc:creator>
<dc:creator>Konmal Ali</dc:creator>
<dc:creator>Nikhil L Chervu</dc:creator>
<dc:creator>Arjun Verma</dc:creator>
<dc:creator>Ming-Sing Si</dc:creator>
<dc:creator>David D'Alessandro</dc:creator>
<dc:creator>Peyman Benharash</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Survival After Cardiac Transplantation in Adults With Single-Ventricle Congenital Heart Disease</dc:title>
<dc:identifier>pmid:37704313</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.037</dc:identifier>
</item>
<item>
<title>Generating High-Quality Outcomes in Children With MAPCAs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704312/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1223-1225. doi: 10.1016/j.jacc.2023.08.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704312/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704312</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.003>10.1016/j.jacc.2023.08.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704312</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Bryan H Goldstein</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Generating High-Quality Outcomes in Children With MAPCAs</dc:title>
<dc:identifier>pmid:37704312</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.003</dc:identifier>
</item>
<item>
<title>20-Year Experience With Repair of Pulmonary Atresia or Stenosis and Major Aortopulmonary Collateral Arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704311/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In a growing pulmonary artery reconstruction program, with increasing volumes and an expanding population of patients who underwent prior surgery, outcomes of patients with pulmonary atresia or stenosis and MAPCAs have continued to improve.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1206-1222. doi: 10.1016/j.jacc.2023.06.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: We have followed a consistent, albeit evolving, strategy for the management of patients with pulmonary atresia or severe stenosis and major aortopulmonary collateral arteries (MAPCAs) that aims to achieve complete repair with low right ventricular pressure by completely incorporating blood supply and relieving stenoses to all lung segments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to characterize our 20-year institutional experience managing patients with MAPCAs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We reviewed all patients who underwent surgery for MAPCAs and biventricular heart disease from November 2001 through December 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the study period, 780 unique patients underwent surgery. The number of new patients undergoing surgery annually was relatively steady during the first 15 years, then increased substantially thereafter. Surgery before referral had been performed in almost 40% of patients, more often in our recent experience than earlier. Complete repair was achieved in 704 patients (90%), 521 (67%) during the first surgery at our center, with a median right ventricular to aortic pressure ratio of 0.34 (25th, 75th percentiles: 0.28, 0.40). The cumulative incidence of mortality was 15% (95% CI: 12%-19%) at 10 years, with no difference according to era of surgery (P = 0.53). On multivariable Cox regression, Alagille syndrome (HR: 2.8; 95% CI: 1.4-5.7; P = 0.004), preoperative respiratory support (HR: 2.0; 95% CI: 1.2-3.3; P = 0.008), and palliative first surgery at our center (HR: 3.5; 95% CI: 2.3-5.4; P &lt; 0.001) were associated with higher risk of death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a growing pulmonary artery reconstruction program, with increasing volumes and an expanding population of patients who underwent prior surgery, outcomes of patients with pulmonary atresia or stenosis and MAPCAs have continued to improve.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704311/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704311</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.041>10.1016/j.jacc.2023.06.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704311</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Doff B McElhinney</dc:creator>
<dc:creator>Ritu Asija</dc:creator>
<dc:creator>Yulin Zhang</dc:creator>
<dc:creator>Ayush Jaggi</dc:creator>
<dc:creator>Jennifer Shek</dc:creator>
<dc:creator>Lynn F Peng</dc:creator>
<dc:creator>M Gail Boltz</dc:creator>
<dc:creator>Michael Ma</dc:creator>
<dc:creator>Elisabeth Martin</dc:creator>
<dc:creator>Frank L Hanley</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>20-Year Experience With Repair of Pulmonary Atresia or Stenosis and Major Aortopulmonary Collateral Arteries</dc:title>
<dc:identifier>pmid:37704311</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.041</dc:identifier>
</item>
<item>
<title>Incidental Coronary Artery Calcium: Nothing Is More Expensive Than a Missed Opportunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704310/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1203-1205. doi: 10.1016/j.jacc.2023.06.039.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704310/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704310</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.039>10.1016/j.jacc.2023.06.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704310</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Roger S Blumenthal</dc:creator>
<dc:creator>Jelani Grant</dc:creator>
<dc:creator>Seamus P Whelton</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Incidental Coronary Artery Calcium: Nothing Is More Expensive Than a Missed Opportunity</dc:title>
<dc:identifier>pmid:37704310</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.039</dc:identifier>
</item>
<item>
<title>Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging With Cardiovascular Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Incidental CAC ≥100 was associated with an increased risk of all-cause death and adverse cardiovascular outcomes, beyond traditional risk factors. DL-CAC from routine non-ECG-gated CTs identifies patients at increased cardiovascular risk and holds promise as a tool for opportunistic screening to facilitate earlier intervention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1192-1202. doi: 10.1016/j.jacc.2023.06.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coronary artery calcium (CAC) is a strong predictor of cardiovascular events across all racial and ethnic groups. CAC can be quantified on nonelectrocardiography (ECG)-gated computed tomography (CT) performed for other reasons, allowing for opportunistic screening for subclinical atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors investigated whether incidental CAC quantified on routine non-ECG-gated CTs using a deep-learning (DL) algorithm provided cardiovascular risk stratification beyond traditional risk prediction methods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Incidental CAC was quantified using a DL algorithm (DL-CAC) on non-ECG-gated chest CTs performed for routine care in all settings at a large academic medical center from 2014 to 2019. We measured the association between DL-CAC (0, 1-99, or ≥100) with all-cause death (primary outcome), and the secondary composite outcomes of death/myocardial infarction (MI)/stroke and death/MI/stroke/revascularization using Cox regression. We adjusted for age, sex, race, ethnicity, comorbidities, systolic blood pressure, lipid levels, smoking status, and antihypertensive use. Ten-year atherosclerotic cardiovascular disease risk was calculated using the pooled cohort equations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 5,678 adults without ASCVD (51% women, 18% Asian, 13% Hispanic/Latinx), 52% had DL-CAC >;0. Those with DL-CAC ≥100 had an average 10-year ASCVD risk of 24%; yet, only 26% were on statins. After adjustment, patients with DL-CAC ≥100 had increased risk of death (HR: 1.51; 95% CI: 1.28-1.79), death/MI/stroke (HR: 1.57; 95% CI: 1.33-1.84), and death/MI/stroke/revascularization (HR: 1.69; 95% CI: 1.45-1.98) compared with DL-CAC = 0.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Incidental CAC ≥100 was associated with an increased risk of all-cause death and adverse cardiovascular outcomes, beyond traditional risk factors. DL-CAC from routine non-ECG-gated CTs identifies patients at increased cardiovascular risk and holds promise as a tool for opportunistic screening to facilitate earlier intervention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704309</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.040>10.1016/j.jacc.2023.06.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704309</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Allison W Peng</dc:creator>
<dc:creator>Ramzi Dudum</dc:creator>
<dc:creator>Sneha S Jain</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Bhavik N Patel</dc:creator>
<dc:creator>Nishith Khandwala</dc:creator>
<dc:creator>David Eng</dc:creator>
<dc:creator>Akshay S Chaudhari</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging With Cardiovascular Outcomes</dc:title>
<dc:identifier>pmid:37704309</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.040</dc:identifier>
</item>
<item>
<title>Complete Coronary Revascularization: A New Strategy to Improve Clinical Outcomes for Stable Coronary Artery Disease?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704308/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1189-1191. doi: 10.1016/j.jacc.2023.07.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704308/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704308</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.008>10.1016/j.jacc.2023.07.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704308</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jane A Leopold</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Complete Coronary Revascularization: A New Strategy to Improve Clinical Outcomes for Stable Coronary Artery Disease?</dc:title>
<dc:identifier>pmid:37704308</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.008</dc:identifier>
</item>
<item>
<title>Focus on atrial fibrillation in specific clinical settings and on calmodulinopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 14;44(35):3299-3302. doi: 10.1093/eurheartj/ehad590.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37704265</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad590>10.1093/eurheartj/ehad590</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704265</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on atrial fibrillation in specific clinical settings and on calmodulinopathy</dc:title>
<dc:identifier>pmid:37704265</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad590</dc:identifier>
</item>
<item>
<title>An immune cell atlas reveals the dynamics of human macrophage specification during prenatal development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37703875/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>Macrophages are heterogeneous and play critical roles in development and disease, but their diversity, function, and specification remain inadequately understood during human development. We generated a single-cell RNA sequencing map of the dynamics of human macrophage specification from PCW 4-26 across 19 tissues. We identified a microglia-like population and a proangiogenic population in 15 macrophage subtypes. Microglia-like cells, molecularly and morphologically similar to microglia in the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 6:S0092-8674(23)00908-X. doi: 10.1016/j.cell.2023.08.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Macrophages are heterogeneous and play critical roles in development and disease, but their diversity, function, and specification remain inadequately understood during human development. We generated a single-cell RNA sequencing map of the dynamics of human macrophage specification from PCW 4-26 across 19 tissues. We identified a microglia-like population and a proangiogenic population in 15 macrophage subtypes. Microglia-like cells, molecularly and morphologically similar to microglia in the CNS, are present in the fetal epidermis, testicle, and heart. They are the major immune population in the early epidermis, exhibit a polarized distribution along the dorsal-lateral-ventral axis, and interact with neural crest cells, modulating their differentiation along the melanocyte lineage. Through spatial and differentiation trajectory analysis, we also showed that proangiogenic macrophages are perivascular across fetal organs and likely yolk-sac-derived as microglia. Our study provides a comprehensive map of the heterogeneity and developmental dynamics of human macrophages and unravels their diverse functions during development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37703875/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37703875</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.019>10.1016/j.cell.2023.08.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37703875</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Zeshuai Wang</dc:creator>
<dc:creator>Zhisheng Wu</dc:creator>
<dc:creator>Hao Wang</dc:creator>
<dc:creator>Ruoqing Feng</dc:creator>
<dc:creator>Guanlin Wang</dc:creator>
<dc:creator>Muxi Li</dc:creator>
<dc:creator>Shuang-Yin Wang</dc:creator>
<dc:creator>Xiaoyan Chen</dc:creator>
<dc:creator>Yiyi Su</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:creator>Weiwen Zhang</dc:creator>
<dc:creator>Yuzhou Bao</dc:creator>
<dc:creator>Zhenwei Lan</dc:creator>
<dc:creator>Zhuo Song</dc:creator>
<dc:creator>Yiheng Wang</dc:creator>
<dc:creator>Xianyang Luo</dc:creator>
<dc:creator>Lingyu Zhao</dc:creator>
<dc:creator>Anli Hou</dc:creator>
<dc:creator>Shuye Tian</dc:creator>
<dc:creator>Hongliang Gao</dc:creator>
<dc:creator>Wenbin Miao</dc:creator>
<dc:creator>Yingyu Liu</dc:creator>
<dc:creator>Huilin Wang</dc:creator>
<dc:creator>Cui Yin</dc:creator>
<dc:creator>Zhi-Liang Ji</dc:creator>
<dc:creator>Mingqian Feng</dc:creator>
<dc:creator>Hongkun Liu</dc:creator>
<dc:creator>Lianghui Diao</dc:creator>
<dc:creator>Ido Amit</dc:creator>
<dc:creator>Yun Chen</dc:creator>
<dc:creator>Yong Zeng</dc:creator>
<dc:creator>Florent Ginhoux</dc:creator>
<dc:creator>Xueqing Wu</dc:creator>
<dc:creator>Yuanfang Zhu</dc:creator>
<dc:creator>Hanjie Li</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An immune cell atlas reveals the dynamics of human macrophage specification during prenatal development</dc:title>
<dc:identifier>pmid:37703875</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.019</dc:identifier>
</item>
<item>
<title>Self-demixing of mRNA copies buffers mRNA:mRNA and mRNA:regulator stoichiometries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37703874/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>Cellular homeostasis requires the robust control of biomolecule concentrations, but how do millions of mRNAs coordinate their stoichiometries in the face of dynamic translational changes? Here, we identified a two-tiered mechanism controlling mRNA:mRNA and mRNA:protein stoichiometries where mRNAs super-assemble into condensates with buffering capacity and sorting selectivity through phase-transition mechanisms. Using C. elegans oogenesis arrest as a model, we investigated the transcriptome...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 7:S0092-8674(23)00907-8. doi: 10.1016/j.cell.2023.08.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cellular homeostasis requires the robust control of biomolecule concentrations, but how do millions of mRNAs coordinate their stoichiometries in the face of dynamic translational changes? Here, we identified a two-tiered mechanism controlling mRNA:mRNA and mRNA:protein stoichiometries where mRNAs super-assemble into condensates with buffering capacity and sorting selectivity through phase-transition mechanisms. Using C. elegans oogenesis arrest as a model, we investigated the transcriptome cytosolic reorganization through the sequencing of RNA super-assemblies coupled with single mRNA imaging. Tightly repressed mRNAs self-assembled into same-sequence nanoclusters that further co-assembled into multiphase condensates. mRNA self-sorting was concentration dependent, providing a self-buffering mechanism that is selective to sequence identity and controls mRNA:mRNA stoichiometries. The cooperative sharing of limiting translation repressors between clustered mRNAs prevented the disruption of mRNA:repressor stoichiometries in the cytosol. Robust control of mRNA:mRNA and mRNA:protein stoichiometries emerges from mRNA self-demixing and cooperative super-assembly into multiphase multiscale condensates with dynamic storage capacity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37703874/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37703874</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.018>10.1016/j.cell.2023.08.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37703874</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrés H Cardona</dc:creator>
<dc:creator>Szilvia Ecsedi</dc:creator>
<dc:creator>Mokrane Khier</dc:creator>
<dc:creator>Zhou Yi</dc:creator>
<dc:creator>Alia Bahri</dc:creator>
<dc:creator>Amira Ouertani</dc:creator>
<dc:creator>Florian Valero</dc:creator>
<dc:creator>Margaux Labrosse</dc:creator>
<dc:creator>Sami Rouquet</dc:creator>
<dc:creator>Stéphane Robert</dc:creator>
<dc:creator>Agnès Loubat</dc:creator>
<dc:creator>Danielle Adekunle</dc:creator>
<dc:creator>Arnaud Hubstenberger</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Self-demixing of mRNA copies buffers mRNA:mRNA and mRNA:regulator stoichiometries</dc:title>
<dc:identifier>pmid:37703874</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.018</dc:identifier>
</item>
<item>
<title>Fractional Flow Reserve-Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37703036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Among patients with MI and FFR-negative nonculprit lesions, the presence of a high-risk plaque is associated with a worse clinical outcome, which is mainly driven by a higher number of unplanned revascularizations. In a population with a high recurrent event rate despite physiology-guided complete revascularization, these results call for research on additional pharmacological or focal treatment strategies in patients harboring high-risk plaques.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 13. doi: 10.1001/jamacardio.2023.2910. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Even after fractional flow reserve (FFR)-guided complete revascularization, patients with myocardial infarction (MI) have high rates of recurrent major adverse cardiovascular events (MACE). These recurrences may be caused by FFR-negative high-risk nonculprit lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the association between optical coherence tomography (OCT)-identified high-risk plaques of FFR-negative nonculprit lesions and occurrence of MACE in patients with MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: PECTUS-obs (Identification of Risk Factors for Acute Coronary Events by OCT After STEMI [ST-segment elevation MI] and NSTEMI [non-STEMI] in Patients With Residual Non-flow Limiting Lesions) is an international, multicenter, prospective, observational cohort study. In patients presenting with MI, OCT was performed on all FFR-negative (FFR >; 0.80) nonculprit lesions. A high-risk plaque was defined containing at least 2 of the following prespecified criteria: (1) a lipid arc at least 90°, (2) a fibrous cap thickness less than 65 μm, and (3) either plaque rupture or thrombus presence. Patients were enrolled from December 14, 2018, to September 15, 2020. Data were analyzed from December 2, 2022, to June 28, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURE: The primary end point of MACE, a composite of all-cause mortality, nonfatal MI, or unplanned revascularization, at 2-year follow-up was compared in patients with and without a high-risk plaque.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 438 patients were enrolled, and OCT findings were analyzable in 420. Among included patients, mean (SD) age was 63 (10) years, 340 (81.0) were men, and STEMI and non-STEMI were equally represented (217 [51.7%] and 203 [48.3%]). A mean (SD) of 1.17 (0.42) nonculprit lesions per patient was imaged. Analysis of OCT images revealed at least 1 high-risk plaque in 143 patients (34.0%). The primary end point occurred in 22 patients (15.4%) with a high-risk plaque and 23 of 277 patients (8.3%) without a high-risk plaque (hazard ratio, 1.93 [95% CI, 1.08-3.47]; P = .02), primarily driven by more unplanned revascularizations in patients with a high-risk plaque (14 of 143 [9.8%] vs 12 of 277 [4.3%]; P = .02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients with MI and FFR-negative nonculprit lesions, the presence of a high-risk plaque is associated with a worse clinical outcome, which is mainly driven by a higher number of unplanned revascularizations. In a population with a high recurrent event rate despite physiology-guided complete revascularization, these results call for research on additional pharmacological or focal treatment strategies in patients harboring high-risk plaques.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37703036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37703036</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2910>10.1001/jamacardio.2023.2910</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37703036</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jan-Quinten Mol</dc:creator>
<dc:creator>Rick H J A Volleberg</dc:creator>
<dc:creator>Anouar Belkacemi</dc:creator>
<dc:creator>Renicus S Hermanides</dc:creator>
<dc:creator>Martijn Meuwissen</dc:creator>
<dc:creator>Alexey V Protopopov</dc:creator>
<dc:creator>Peep Laanmets</dc:creator>
<dc:creator>Oleg V Krestyaninov</dc:creator>
<dc:creator>Robert Dennert</dc:creator>
<dc:creator>Rohit M Oemrawsingh</dc:creator>
<dc:creator>Jan-Peter van Kuijk</dc:creator>
<dc:creator>Karin Arkenbout</dc:creator>
<dc:creator>Dirk J van der Heijden</dc:creator>
<dc:creator>Saman Rasoul</dc:creator>
<dc:creator>Erik Lipsic</dc:creator>
<dc:creator>Laura Rodwell</dc:creator>
<dc:creator>Cyril Camaro</dc:creator>
<dc:creator>Peter Damman</dc:creator>
<dc:creator>Tomasz Roleder</dc:creator>
<dc:creator>Elvin Kedhi</dc:creator>
<dc:creator>Maarten A H van Leeuwen</dc:creator>
<dc:creator>Robert-Jan M van Geuns</dc:creator>
<dc:creator>Niels van Royen</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Fractional Flow Reserve-Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction</dc:title>
<dc:identifier>pmid:37703036</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2910</dc:identifier>
</item>
<item>
<title>Long-Term Quality of Life After Out-of-Hospital Cardiac Arrest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37703007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Among this survey study's responders, who comprised more than 50% of survivors of out-of-hospital cardiac arrest in Denmark, long-term health-related quality of life up to 20 years after their event was consistently high and comparable to that of the general population. These findings support resource allocation and efforts targeted to increasing survival after out-of-hospital cardiac arrest.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 13. doi: 10.1001/jamacardio.2023.2934. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Allocating resources to increase survival after cardiac arrest requires survivors to have a good quality of life, but long-term data are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the quality of life of survivors of out-of-hospital cardiac arrest from 2001 to 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This survey study used the EuroQol Health Questionnaire, 12-Item Short Form Health Survey (SF-12), and Hospital Anxiety and Depression Scale (HADS) to assess the health-related quality of life of all adult survivors of out-of-hospital cardiac arrest included in the Danish Cardiac Arrest Registry between June 1, 2001, and August 31, 2019, who were alive in October 2020 (follow-up periods, 0-1, >;1-2, >;2-4, >;4-6, >;6-8, >;8-10, >;10-15, and >;15-20 years since arrest). The survey was conducted from October 1, 2020, through May 31, 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: All patients who experienced an out-of-hospital cardiac arrest.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: Self-reported health was measured using the EuroQol Health Questionnaire index (EQ index) score and EQ visual analog scale. Physical and mental health were measured using the SF-12, and anxiety and depression were measured using the HADS. Descriptive statistics were used for the analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4545 survivors, 2552 (56.1%) completed the survey, with a median follow-up since their event of 5.5 years (IQR, 2.9-8.9 years). Age was comparable between responders and nonresponders (median [IQR], 67 [58-74] years vs 68 [56-78] years), and 2075 responders (81.3%) were men and 477 (18.7%) women (vs 1473 male [73.9%] and 520 female [26.1%] nonresponders). For the shortest follow-up (0-1 year) and longest follow-up (>;15-20 years) groups, the median EQ index score was 0.9 (IQR, 0.7-1.0) and 0.9 (0.8-1.0), respectively. For all responders, the mean (SD) SF-12 physical health score was 43.3 (12.3) and SF-12 mental health score, 52.9 (8.3). All 3 scores were comparable to a general Danish reference population. Based on HADS scores, a low risk for anxiety was reported by 73.0% (54 of 74) of 0- to 1-year survivors vs 89.3% (100 of 112) of greater than 15- to 20-year survivors; for symptoms of depression, these proportions were 79.7% (n = 59) and 87.5% (n = 98), respectively. Health-related quality of life was similar in survivor groups across all follow-up periods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among this survey study's responders, who comprised more than 50% of survivors of out-of-hospital cardiac arrest in Denmark, long-term health-related quality of life up to 20 years after their event was consistently high and comparable to that of the general population. These findings support resource allocation and efforts targeted to increasing survival after out-of-hospital cardiac arrest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37703007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37703007</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2934>10.1001/jamacardio.2023.2934</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37703007</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Harman Yonis</dc:creator>
<dc:creator>Kathrine Kold Sørensen</dc:creator>
<dc:creator>Henrik Bøggild</dc:creator>
<dc:creator>Kristian Bundgaard Ringgren</dc:creator>
<dc:creator>Carolina Malta Hansen</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Fredrik Folke</dc:creator>
<dc:creator>Helle Collatz Christensen</dc:creator>
<dc:creator>Britta Jensen</dc:creator>
<dc:creator>Mikkel Porsborg Andersen</dc:creator>
<dc:creator>Vicky L Joshi</dc:creator>
<dc:creator>Ann-Dorthe Zwisler</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Kristian Kragholm</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Quality of Life After Out-of-Hospital Cardiac Arrest</dc:title>
<dc:identifier>pmid:37703007</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2934</dc:identifier>
</item>
<item>
<title>Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37703006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In patients with refractory hypercholesterolemia, evinacumab provided sustained reductions in LDL-C level and was generally well tolerated.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 13. doi: 10.1001/jamacardio.2023.2921. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Patients with refractory hypercholesterolemia who do not achieve their guideline-defined low-density lipoprotein cholesterol (LDL-C) thresholds despite treatment with maximally tolerated combinations of lipid-lowering therapies (LLTs) have an increased risk of atherosclerotic cardiovascular disease (ASCVD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial included a 2-week screening period followed by a 16-week double-blind treatment period (DBTP) for subcutaneous regimens (evinacumab, 450 mg, once weekly [QW]; evinacumab, 300 mg, QW; evinacumab, 300 mg, every 2 weeks; or placebo QW) or a 24-week DBTP for intravenous regimens (evinacumab, 15 mg/kg, every 4 weeks [Q4W]; evinacumab, 5 mg/kg, Q4W; or placebo Q4W); a 48-week open-label treatment period (OLTP) for intravenous treatment only; and a 24-week follow-up period. Patients from 85 sites across 20 countries were recruited for the study; patients with primary hypercholesterolemia (defined as heterozygous familial hypercholesterolemia or established clinical ASCVD without familial hypercholesterolemia) who entered the 48-week OLTP were included. In addition, the patients' hypercholesterolemia was refractory to maximally tolerated LLTs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: All patients entering the OLTP received evinacumab, 15 mg/kg, intravenously Q4W.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Efficacy outcomes included change in LDL-C level and other lipid/lipoprotein parameters from baseline to week 72 (end of the OLTP). Safety outcomes included assessment of treatment-emergent adverse events (TEAEs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 96 patients (mean [SD] age, 54.4 [11.3] years; 52 female [54.2%]) entered the OLTP, of whom 88 (91.7%) completed the OLTP. Mean (SD) baseline LDL-C level was 145.9 (55.2) mg/dL. At week 72, evinacumab, 15 mg/kg, reduced mean (SD) LDL-C level from baseline by 45.5% (28.7%) in the overall cohort. Evinacumab, 15 mg/kg, reduced mean (SD) apolipoprotein B (38.0% [22.1%]), non-high density lipoprotein cholesterol (48.4% [23.2%]), total cholesterol (42.6% [17.5%]), and median (IQR) fasting triglyceride (57.2% [65.4%-44.4%]) levels at week 72 from baseline in the overall cohort. TEAEs occurred in 78 of 96 patients (81.3%). Serious TEAEs occurred in 9 of 96 patients (9.4%); all were considered unrelated to study treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In patients with refractory hypercholesterolemia, evinacumab provided sustained reductions in LDL-C level and was generally well tolerated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03175367.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37703006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37703006</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2921>10.1001/jamacardio.2023.2921</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37703006</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Lesley J Burgess</dc:creator>
<dc:creator>Christoph F Ebenbichler</dc:creator>
<dc:creator>Seth J Baum</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>Shazia Ali</dc:creator>
<dc:creator>Nagwa Khilla</dc:creator>
<dc:creator>Jennifer McGinniss</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Robert Pordy</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia</dc:title>
<dc:identifier>pmid:37703006</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2921</dc:identifier>
</item>
<item>
<title>Error in Figure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37702722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 1;8(9):891. doi: 10.1001/jamacardio.2023.3311.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37702722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37702722</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3311>10.1001/jamacardio.2023.3311</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37702722</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure</dc:title>
<dc:identifier>pmid:37702722</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3311</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37702721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230914160826&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 1;8(9):802. doi: 10.1001/jamacardio.2022.3452.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37702721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230914160826&v=2.17.9.post6+86293ac">37702721</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2022.3452>10.1001/jamacardio.2022.3452</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37702721</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:37702721</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2022.3452</dc:identifier>
</item>





























</channel>
</rss>